Immune-Related Adverse Events and Survival Outcomes in NSCLC
Episode description
This week, we're focusing on lung cancer—first, with a report on how therapy-related adverse events experienced by patients with lung cancer treated with immunotherapy may help to predict survival outcomes; and second, with a video about disparities in certain populations when it comes to lung cancer screening and treatment.
Coverage of stories discussed this week on ascopost.com:
To listen to more podcasts from ASCO, visit asco.org/podcasts.
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we're focusing on lung cancer—first, with a report on how therapy-related adverse events experienced by patients with lung cancer treated with immunotherapy may help to predict survival outcomes; and second, with a video about disparities in certain populations when it comes to lung cancer screening and treatment.This week, we're focusing on lung cancer—first, with a report on how therapy-related adverse events experienced by patients with lung cancer treated with immunotherapy may help to predict survival outcomes; and second, with a video about disparities in certain populations when it comes to lung cancer screening and treatment.
Coverage of stories discussed this week on ascopost.com:
To listen to more podcasts from ASCO, visit asco.org/podcasts.
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Coverage of stories discussed this week on ascopost.com:This week, we're focusing on lung cancer—first, with a report on how therapy-related adverse events experienced by patients with lung cancer treated with immunotherapy may help to predict survival outcomes; and second, with a video about disparities in certain populations when it comes to lung cancer screening and treatment.
Coverage of stories discussed this week on ascopost.com:
To listen to more podcasts from ASCO, visit asco.org/podcasts.
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Multisystem Immune-Related Adverse Events and Disease Outcomes Among Patients With NSCLC Treated With Immunotherapy